Last checked at 25 Jan 2013 15:27
Port Erin Biopharma Investments Limited ("the Company")
Net Asset Value calculation to 31st December 2012
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 December 2012 was 9.50 pence per share, including un-invested cash of £101,241. The portfolio is valued under IFRS at bid price. This quarter's NAV represents a small decrease from the previous valuation of 9.63 pence per share, which included un-invested cash of £329,708. The revenue reserve has increased substantially following the deduction of listing expenses from the share premium account and still represents a return of over 16.0% on investments after operating costs. Indeed, if the NAV valuation were to be published today, the NAV per share would approach 10.4 pence."
| Unaudited 15 September 2011 to 31 December 2012 £ | |
Fixed Assets |
|
|
| Investments
| 3,031,135 |
Current Assets |
|
|
| Debtors: amounts owing | 9,035 |
| Un-invested cash
| 101,241 |
Current Liabilities |
|
|
| Creditors: amounts due
| (7,292) |
|
| 3,134,119 |
Capital and Reserves |
|
|
| Share Capital | 33 |
| Share Premium | 2,699,011 |
| Capital reserve - realised | 0 |
| Capital reserve - unrealised | 0 |
| Revenue reserve
| 435,075 |
| 3,134,119 | |
| ||
Shares in Issue
| 33,000,000 | |
Net Asset Value per share
| 9.50 pence |
--- ENDS ---
Portfolio Details
Investments Schedule at 31st December 2012 | Valuation £ | Portfolio % |
Summit Corporation plc | £269,166.87 | 8.88% |
Cytox Limited | £200,000.00 | 6.60% |
Gilead Sciences Inc. | £195,452.13 | 6.45% |
Synergy Pharmaceuticals Inc. | £182,814.82 | 6.03% |
Plethora Solutions Holdings plc | £180,000.00 | 5.94% |
Celgene Inc. | £141,125.68 | 4.66% |
Astellas Pharma Inc. | £140,762.00 | 4.64% |
Arrowhead Resources | £135,419.97 | 4.47% |
TrovaGene Inc. | £127,845.13 | 4.22% |
Abbott Laboratories | £117,762.25 | 3.89% |
Pfizer Inc. | £114,835.48 | 3.79% |
£1,805,184.33 | 59.55% | |
| ||
Aggregate value of remaining holdings below 3% of total portfolio | £1,225,950.25 | 40.45% |
| ||
TOTAL INVESTMENTS | £3,031,134.58 | 100.00% |
For further information, please contact:
Port Erin Biopharma Investments Ltd | Libertas Capital Corporate Finance Limited | Peterhouse Capital Limited |
The Company | Nomad | Broker |
Denham Eke +44 162 463 9396 | Sandy Jamieson +44 207 569 9650 | Jon Levinson +44 207 562 3350 |